Celldex Therapeutics, Inc. (CLDX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Celldex Therapeutics, Inc.'s filing signal turned negative.

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic antibodies targeting mast cell biology for severe inflammatory, allergic, and autoimmune diseases. The company's lead candidate, barzolvolimab, a humanized monoclonal antibody targeting KIT, is in late-stage development for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), with ongoing Phase 2 studies in prurigo nodularis and atopic dermatitis. Celldex also has a bispecific antibody platform, with CDX-622 targeting TSLP and SCF, currently in Phase 1 trials. The company has no commercial revenues and has historically incurred operating losses, relying on cash reserves and potential future financing to fund its research and development activities.

The company has had no commercial revenues from sales of its drug candidates. Revenue is derived from product development agreements with collaborative partners for research and development services, and contract manufacturing and research and development arrangements.